Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

For the Liu Lab, necessity is truly the mother of invention. The researchers were examining how the 3D organization of the ...

Our DNA is constantly under threat — from cell division errors to external factors like sunlight and smoking. Fortunately, ...

A new study from Memorial Sloan Kettering Cancer Center has shown that an RNA-based neoantigen vaccine can generate ...

Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

KRRO-110 is the first RNA editing development candidate from Korro's proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Researchers at the RNA Institute at the University at Albany are pioneering new methods for designing and assembling DNA ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...